BMY — BRISTOL MYERS SQUIBB CO
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 14272 ·
Last close
$62.86
Market Cap
$128.41B
52W High
$68.64
52W Low
$41.13
ADV30
9,797,667
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 11,489,000,000 | 8,068,000,000 | 3,365,000,000 | 2,677,000,000 | 86,476,000,000 | 9,574,000,000 | 66,374,000,000 |
| Dec 2025 | 12,503,000,000 | 8,406,000,000 | 2,813,000,000 | 1,087,000,000 | 90,038,000,000 | 10,209,000,000 | 71,532,000,000 |
| Sep 2025 | 12,222,000,000 | 8,787,000,000 | 3,639,000,000 | 2,201,000,000 | 96,889,000,000 | 15,726,000,000 | 78,289,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$12,782,000,000
Investing CF
$-4,905,000,000
Financing CF
$-11,709,000,000
CapEx
$-1,342,000,000
Dividends Paid
$-5,095,000,000
Buybacks
$0
EPS Diluted TTM
$4.54
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$20,316,000,000
Inventory
$2,737,000,000
Receivables
$12,999,000,000
ST Investments
$2,345,000,000
EBIT TTM
$13,640,000,000
Pretax Income TTM
$11,910,000,000
Interest Exp TTM
$1,730,000,000
Analysts
23
Yahoo Snapshot (yfinance, live)
Total Revenue
$49,186,000,896
EBITDA
$18,929,999,872
Free Cash Flow
$8,114,375,168
Enterprise Value
$163,984,359,424
Total Cash
$11,066,999,808
Total Debt
$45,053,001,728
Shares Out
2,042,714,656
Trailing EPS
$4.54
Book Value
$10.93
ROE
46.6%
ROA
10.7%
Div Yield
3.96%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 48,195,000,000 | 13,724,000,000 | 7,054,000,000 | 90,038,000,000 | 71,532,000,000 | 18,473,000,000 | 14,156,000,000 |
| Dec 2024 | 48,300,000,000 | 5,887,000,000 | -8,948,000,000 | 92,603,000,000 | 76,215,000,000 | 16,335,000,000 | 15,190,000,000 |
| Dec 2023 | 45,006,000,000 | 8,195,000,000 | 8,025,000,000 | 95,159,000,000 | 65,674,000,000 | 29,430,000,000 | 13,860,000,000 |
| Dec 2022 | 46,159,000,000 | 9,104,000,000 | 6,327,000,000 | 96,820,000,000 | 65,702,000,000 | 31,061,000,000 | 13,066,000,000 |
TTM Snapshot
Revenues TTM
$45,277,000,000
NetIncome TTM
$7,201,000,000
OpCashFlow TTM
$0
Assets (Latest)
$90,038,000,000
Forward EPS
$6.56
Max Pain — expiry 2026-10-02 (volume-derived — Yahoo OI feed degraded)
max pain strike: $62.00 · spot: $62.86 · call volume: 2,349 · put volume: 3,902
Expected Move to 2026-10-02:
±$2.09
(3.32%) —
implied range
$60.77 –
$64.95
· ATM straddle on $63.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVO | NOVO NORDISK A S | $129.75B | $38.80 | — |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $133.37B | $526.19 | — |
| PFE | PFIZER INC | $163.41B | $28.67 | — |
| GSK | GSK plc | $98.62B | $49.24 | — |
| SNY | Sanofi | $98.51B | $41.11 | — |
News headlines (Yahoo Finance, 1h cache)
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
2026-09-27 22:20 · Yahoo
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
2026-09-25 14:00 · Yahoo
Bristol Myers Squibb (BMY) Adds Restricted Pharmacy Path For New Myeloma Drug
2026-09-24 22:15 · Yahoo
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
2026-09-24 12:16 · Yahoo
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?
2026-09-24 11:56 · Yahoo
New Strong Buy Stocks for September 24th
2026-09-24 08:50 · Yahoo
Over $3.6M Raised to Build a More Connected Future of Mental Health at 32nd One Mind Music Festival Featuring The Fray
2026-09-23 19:11 · Yahoo
New Member Alert: RAAP WELCOMES BRISTOL MYERS SQUIBB! BMS Joins as Newest Member of RAAP
2026-09-23 14:01 · Yahoo
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review
2026-09-27 16:02 · Yahoo
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
2026-09-26 01:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.